Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001233197 | SCV001405780 | uncertain significance | Pyogenic arthritis-pyoderma gangrenosum-acne syndrome | 2019-08-02 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C55"). This variant has not been reported in the literature in individuals with PSTPIP1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with alanine at codon 252 of the PSTPIP1 protein (p.Val252Ala). The valine residue is highly conserved and there is a small physicochemical difference between valine and alanine. |
Ambry Genetics | RCV002563793 | SCV003584527 | uncertain significance | Inborn genetic diseases | 2021-09-17 | criteria provided, single submitter | clinical testing | The c.755T>C (p.V252A) alteration is located in exon 11 (coding exon 11) of the PSTPIP1 gene. This alteration results from a T to C substitution at nucleotide position 755, causing the valine (V) at amino acid position 252 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |